Evidence map›Paper›PMID 34054542›Full record

ReviewFrontiers in pharmacology2021

Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease.

Annunziata Nusca, Dario Tuccinardi, Silvia Pieralice, Sara Giannone, Myriam Carpenito, Lavinia Monte, Mikiko Watanabe, Ilaria Cavallari, Ernesto Maddaloni, Gian Paolo Ussia and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Diabetic Platelets: Pathophysiology, Clinical Significance, and Therapeutic Perspectives.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  8. Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.American journal of preventive cardiology · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia.International journal of environmental research and public health · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Annunziata NuscaUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Dario TuccinardiUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Silvia PieraliceUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Sara GiannoneUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Myriam CarpenitoUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Lavinia MonteUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Mikiko WatanabeDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy.
Ilaria CavallariUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Ernesto MaddaloniDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Gian Paolo UssiaUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Silvia ManfriniUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.
Francesco GrigioniUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In type 2 diabetes, anti-thrombotic management is challenging, and current anti-platelet agents have demonstrated reduced efficacy. Old and new anti-diabetic drugs exhibited-besides lowering blood glucose levels-direct and indirect effects on platelet function and on thrombotic milieu, eventually conditioning cardiovascular outcomes. The present review summarizes existing evidence on the effects of glucose-lowering agents on platelet properties, addressing pre-clinical and clinical research, as well as drug-drug interactions with anti-platelet agents. We aimed at expanding clinicians' understanding by highlighting new opportunities for an optimal management of patients with diabetes and cardiovascular disease. We suggest how an improvement of the thrombotic risk in this large population of patients may be achieved by a careful and tailored combination of anti-diabetic and anti-platelet therapies.

Indexed as

anti-diabetic therapiesanti-platelet agentscardiovascular diseasediabetesglucose-lowering drugsplateletthrombotic risk

Identifiers

PMID34054542
PMCPMC8149960

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.